A5061937590- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Gene expression and cancer classification
- HER2/EGFR in Cancer Research
- Lung Cancer Research Studies
- Genetic factors in colorectal cancer
- Lung Cancer Diagnosis and Treatment
- Advanced Biosensing Techniques and Applications
- Cell Image Analysis Techniques
- Renal cell carcinoma treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- BRCA gene mutations in cancer
- ECG Monitoring and Analysis
- Phonocardiography and Auscultation Techniques
- Complement system in diseases
- Platelet Disorders and Treatments
- Melanoma and MAPK Pathways
- PI3K/AKT/mTOR signaling in cancer
- Immune cells in cancer
- Cardiac electrophysiology and arrhythmias
International Association for the Study of Lung Cancer
2024
Seattle Children's Hospital
2022-2024
University of Washington
2024
University of California, Irvine
2020-2023
University of Arizona
2019
Moores Cancer Center
2017
Dynavax Technologies (Germany)
2016
Queen's University
2016
University of California, San Diego
2015
Yale Cancer Center
2015
Clinical trials of the KRAS inhibitors adagrasib and sotorasib have shown promising activity in cancers harboring glycine-to-cysteine amino acid substitutions at codon 12 (KRAS
Checkpoint inhibitors have demonstrated efficacy in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). However, the majority of do not benefit from these agents. To improve checkpoint inhibitors, intratumoral (i.t.) injection innate immune activators, TLR7 TLR9 agonists, were tested along programmed death-1 receptor (PD-1) blockade. The combination therapy suppressed tumor growth at primary injected distant sites human papillomavirus-negative (HPV-negative)...
Catastrophic antiphospholipid syndrome (CAPS) is a rare and life-threatening manifestation of (APS). Diagnosing CAPS can be particularly challenging, especially due to significant overlap in pathophysiology, signs, symptoms with other complex hematologic conditions, including thrombotic microangiopathies (TMA) immune-mediated thrombocytopenia (ITP). In many cases, definitive diagnosis not clear, leading delays care poor outcomes. Here, we present an elderly patient previously diagnosed APS...
Toll-like receptors (TLRs) in the innate immune system recognize specific pathogen-associated molecular patterns derived from microbes. Synthetic small molecule TLR7 agonists have been extensively evaluated as topical agents for antiviral and anticancer therapy, adjuvants vaccine. However, safe reproducible administration of synthetic ligands has difficult to achieve due undesirable pharmacokinetics unacceptable side effects. Here, we conjugated a versatile low weight ligand various...
The epidermal growth factor receptor family member ERBB4 stimulates cholesterol biosynthesis in breast epithelial cells.
Abstract: Mesenchymal-epithelial transition (MET) receptor tyrosine kinase is overexpressed, amplified, or mutated in 1– 20% of NSCLC. MET dysregulation associated with a poor prognosis. Recently, development targeted therapies against exon 14 mutations has demonstrated efficacy and tolerability early trials. Here we focus on tepotinib capmatinib regards to molecular characteristics, preclinical clinical data, the emerging role future studies practice. Keywords: tepotinib, capmatinib,...
Two ROS1 tyrosine kinase inhibitors have been approved for fusion positive (ROS1+) non-small cell lung cancer (NSCLC) tumors. We performed a pan-tumor analysis of the incidence fusions to assess if more ROS1+ patients who could benefit from TKIs be identified.A retrospective solid malignancies identified by targeted RNA sequencing and whole transcriptome clinical tumor samples at Caris Life Science (Phoenix, AZ).A total 259 were approximately 175,350 tumors that underwent next-generation...
Abstract: Thirteen percent of non-small cell lung cancer (NSCLC) patients are estimated to have the KRAS G12C mutation. Sotorasib is a novel inhibitor that has shown promising results in preclinical and clinical studies, granting its conditional approval by FDA May 2021. The phase I trial resulted confirmed response 32% progression free survival (PFS) 6.3 months while II 37.1% PFS 6.8 months. It was also be tolerable with most subjects experiencing grade one or two adverse events, commonly...
A novel CD74-NRG2α fusion has recently been identified in NSCLC. We surveyed a large tumor database comprehensively profiled by whole transcriptome sequencing to investigate the incidence and distribution of NRG2 fusions among various solid tumors.Tumor samples submitted for clinical molecular profiling at Caris Life Sciences (Phoenix, AZ) that underwent (NovaSeq [Illumina, San Diego, CA]) were retrospectively analyzed events. All with sufficient reads (> three junctional spanning ≥ seven...
Gastrointestinal (GI) malignancies represent a heterogeneous group of diseases. Traditional tumor markers, though part standard-of-care, lack sensitivity and specificity. Tumor-informed circulating DNA (ctDNA) assay-based molecular residual disease assessment as well recurrence treatment response monitoring can serve robust tool in patients with wide range GI ethnicities.A personalized, tumor-informed multiplex PCR-NGS assay (SignateraTM) was used for the detection quantification ctDNA 258...
Adjuvant cisplatin-based chemotherapy is considered the standard of care for resected stage IB (tumor ≥ 4m)-IIIA non-small cell lung cancer (NSCLC). The ADAURA trial a randomized placebo-controlled Phase III that demonstrated statistically significant improved disease-free survival (DFS) with use 3-years adjuvant osimertinib in IB-IIIA NSCLC harboring epidermal growth factor receptor (EGFR) del 19 or L858R mutations. Subgroup analysis revealed DFS improvement independent primary analysis. A...